Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa

Factores de riesgo para desarrollar carcinoma hepatocelular en pacientes tratados con antivirales de acción directa

Resumen: Introducción y objetivo: La hepatitis C crónica es de las principales causas de cirrosis hepática. El tratamiento con antivirales de acción directa (AAD) mejora la supervivencia. Existe controversia si los AAD generan un incremento del riesgo para desarrollar carcinoma hepatocelular (CHC)....

Full description

Bibliographic Details
Main Authors:	I. Santana-Salgado, A. Bautista-Santos, R. Moreno-Alcántar
Format:	Article
Language:	Spanish
Published:	Elsevier 2022-10-01
Series:	Revista de Gastroenterología de México
Subjects:	Chronic hepatitis C Direct-acting antivirals Hepatocellular carcinoma
Online Access:	http://www.sciencedirect.com/science/article/pii/S0375090621001269

Similar Items

Comportamiento virológico de pacientes con hepatitis C tratados con antivirales cubanos
by: Sahilí Corrales Alonso, et al.

Coste y efectividad de los nuevos antivirales para la hepatitis C.
by: Sabela Lens, et al.
Published: (2015-10-01)

Hepatocellular carcinoma in hepatitis C virus patients treated with direct acting antivirals (DAAs) and patients not exposed to DAAs: a large center comparative study
by: Mohamed Elgazzar, et al.
Published: (2024-05-01)

Impact of treating chronic hepatitis C infection with direct-acting antivirals on the risk of hepatocellular carcinoma recurrence
by: Nevine Ibrahim Musa, et al.
Published: (2020-07-01)

Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C Treated with Direct-Acting Antivirals
by: Cassia Leal, et al.
Published: (2023-01-01)

Direct-acting antivirals: a new strategy in the treatment of hepatitis C virus infection in patients with cirrhosis
by: Mariana Avricenco
Published: (2019-12-01)

Comparison of the efficacy and safety of direct-acting antiviral therapy with or without hepatitis C-related hepatocellular carcinoma
by: Byung Soo Kwan, et al.
Published: (2021-03-01)

Actuación de enfermería ante un paciente con infección aguda por el virus de la hepatitis C en hemodiálisis en tratamiento con antivirales de acción directa
by: Antonio López González, et al.
Published: (2017-12-01)

Direct-acting antiviral agents and risk of Hepatocellular carcinoma: Critical appraisal of the evidence
by: Ciro Celsa, et al.
Published: (2022-01-01)

Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy
by: Ming‐Lun Yeh, et al.
Published: (2021-02-01)

Efectividad del tratamiento con agentes antivirales directos en pacientes con coinfección por VHC y VIH. Estudio de cohorte multicéntrico
by: David Rial-Crestelo, et al.

Risk Factors Contributing to the Occurrence and Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus Patients Treated with Direct-Acting Antivirals
by: Sara Kishta, et al.
Published: (2020-06-01)

Serum Angiopoietin-2 Predicts the Occurrence and Recurrence of Hepatocellular Carcinoma after Direct-Acting Antiviral Therapy for Hepatitis C
by: Naoki Kawagishi, et al.
Published: (2023-01-01)

Changes in patient background and prognosis after hepatectomy for hepatocellular carcinoma by hepatitis virus infection status: New trends in Japan
by: Yukiyasu Okamura, et al.
Published: (2021-07-01)

A validation study of after direct‐acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct‐acting antiviral therapy and achieved sustained virological response
by: Toshifumi Tada, et al.
Published: (2022-01-01)

HCV-Specific T Cell Responses During and After Chronic HCV Infection
by: Hendrik Luxenburger, et al.
Published: (2018-11-01)

Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review
by: Lorenzo Lani, et al.
Published: (2024-02-01)

Carcinoma hepatocelular: parte 2. Tratamento Hepatocelular carcinoma: part 2. Therapy
by: Vinício Paride CONTE
Published: (2000-04-01)

Prognosis Following Sustained Virologic Response in Korean Chronic Hepatitis C Patients Treated with Sofosbuvir-Based Treatment: Data from a Multicenter Prospective Observational Study up to 7 Years
by: Yewan Park, et al.
Published: (2024-07-01)

Efficacy of Direct Acting Antivirals (DAA) therapy in patients with recurrent hepatitis C after liver and kidney transplantation: a cross-sectional study
by: Mehdi Kashani, et al.
Published: (2024-10-01)

Hepatitis C Virus Infection in Europe
by: Margarida Simão, et al.
Published: (2024-09-01)

Treating Hepatitis C Virus Infection in Jails as an Offset to Declines in Treatment Activity in the Community, New York City, NY, 2014–2020
by: Justin Chan, MD, et al.
Published: (2024-04-01)

Chronic Hepatitis C Treatment with New Antiviral Agents
by: Özlem KANDEMİR
Published: (2018-12-01)

Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
by: Kwang Il Seo, et al.
Published: (2017-03-01)

New treatment of hepatitis C (Direct Acting Antiviral)
by: Mohsen Akhondi-Meybodi
Published: (2019-10-01)

Direct-Acting Antiviral Therapy Outcomes in Canadian Chronic Hepatitis C Telemedicine Patients
by: Curtis L. Cooper, et al.
Published: (2017-11-01)

Direct-Acting Antiviral Therapy for Hepatitis C Virus in Patients with BCLC Stage B/C Hepatocellular Carcinoma
by: Shou-Wu Lee, et al.
Published: (2022-10-01)

Clinical impact of normal alanine aminotransferase on direct‐acting antiviral outcome in patients with chronic hepatitis C virus infection
by: Satoru Joshita, et al.
Published: (2020-08-01)

Particularidades del carcinoma hepatocelular en los pacientes con cirrosis hepática Special features of hepatocellular carcinoma in patients presenting with liver cirrhosis
by: Marlen Ivón Castellanos Fernández, et al.
Published: (2011-03-01)

Attach importance to antiviral therapy in patients with hepatocellular carcinoma caused by hepatitis virus
by: Shuling Wu, et al.
Published: (2023-01-01)

Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis
by: D T Abdurakhmanov
Published: (2013-10-01)

Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs
by: Caiyun Yang, et al.
Published: (2025-03-01)

De novo hepatocellular carcinoma occurrence in hepatitis C cirrhotics treated with direct-acting antiviral agents
by: Gabriela Kuftinec, et al.
Published: (2018-01-01)

Assessment of Liver Stiffness Regression and Hepatocellular Carcinoma Risk in Chronic Hepatitis C Patients after Treatment with Direct-Acting Antiviral Drugs
by: Martynas Ridziauskas, et al.
Published: (2021-02-01)

Repeated Measurement of FIB-4 to Predict Long-Term Risk of HCC Development Up to 10 Years After SVR
by: Zou Y, et al.
Published: (2022-12-01)

Characteristics of hepatocellular carcinoma in patients with hepatitis C virus who received direct‐acting antiviral therapy and achieved sustained virological response: The impact of a hepatologist on surveillance
by: Toshifumi Tada, et al.
Published: (2022-07-01)

Hepatocellular carcinoma after a sustained virological response by direct‐acting antivirals harbors TP53 inactivation
by: Taisuke Imamura, et al.
Published: (2022-04-01)

Is hepatitis C direct-acting antiviral therapy a risk factor for the development and recurrence of hepatocellular carcinoma? Narrative literature review and clinical practice recommendations
by: Carolina Delgado Martínez, et al.
Published: (2021-03-01)

Carcinoma hepatocelular apresentado por metástase óssea
by: Orlando Jorge Martins Torres, et al.

Current Treatment Of Chronıc Hepatıtıs C Genotype 1
by: Mesut Aydın, et al.
Published: (2018-10-01)